OR WAIT null SECS
March 03, 2023
EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.
March 02, 2023
Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.
March 01, 2023
AstraZeneca has entered into a global exclusive license agreement with KYM Biosciences for CMG901, which is being investigated as a gastric cancer treatment.
February 24, 2023
Moderna will leverage Life Edit’s suite of gene editing technologies to advance development of in vivo gene editing therapies.
AbbVie and Capsida have expanded their existing collaboration to advance three new gene therapy programs.
The goal of this collaboration is to develop an approach to personalized radiotherapy and drug discovery that is based in genomics and artificial intelligence.
February 21, 2023
LIfT and Minaris will work together to develop a manufacturing process for LIfT’s allogeneic neutrophil progenitor cell therapy.
February 15, 2023
Takeda’s acquisition of Nimbus Lakshmi will grant them rights to NDI-034858, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases.
GenScript PrioBio and Bio Immunitas will work together to develop and fast track manufacturing of a novel therapeutic platform.
January 31, 2023
AstraZeneca and Thermo Fisher will collaborate to develop a solid tissue and blood-based companion diagnostic test for osimertinib.